secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001213900-26-002329
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper reports 67% complete response at week 12 in additional BEACON CSU patients; dose selected for Phase 2b
--------------------------------------------------------------------------------

- 67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.
- In open-label extension, 58% of 36 CSU patients achieved complete response and 75% achieved CR or well-controlled at week 12.
- Median follow-up of 205 days in 63 patients; KIT-related AEs were infrequent, low-grade, and resolved without discontinuation.
- Company plans to commence Phase 2b study of briquilimab in CSU in second half of 2026.
- Briquilimab is an investigational anti-KIT antibody targeting mast-cell-driven diseases like CSU and CIndU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026002329/0001213900-26-002329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026002329/ea0272248-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-002329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer